| Old Articles: <Older 1631-1640 Newer> |
|---|
 |
IndustryWeek
January 1, 2005
Tonya Vinas |
CEO of the Year -- Medicine Man Kevin Sharer has been a frontline eyewitness to the eye-popping technological leaps of the past decade -- leaps that have forever changed the landscape of drug-treatment and global manufacturing. Can the Amgen CEO's formula for success invigorate your company?   |
The Motley Fool
December 22, 2004
W.D. Crotty |
ImmuCell's New Santa Pfizer licenses an ImmuCell development and sends the company's stock skyrocketing. |
The Motley Fool
December 22, 2004
Meyers & Meyers |
The 10-Bagger You've Been Waiting For IntegraMed America looks like the classic Peter Lynch investment. IntegraMed is the only company that packages products and services for fertility centers that offer IVF. |
The Motley Fool
December 21, 2004
Rich Duprey |
Chiron Requests a Second Thought Had the vaccine maker simply issued a press release with the incorrect information, it might be understandable, but investors might feel more at ease if it had gotten it right when it filed documents with the SEC. |
The Motley Fool
December 21, 2004
Brian Gorman |
Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads. |
The Motley Fool
December 21, 2004
Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
The Motley Fool
December 21, 2004
Seth Jayson |
Buy Drug Fears? When headlines get bad, both value hunters and rule breakers should start feeling good about buying stock. |
The Motley Fool
December 20, 2004
Brian Gorman |
Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
| <Older 1631-1640 Newer> Return to current articles. |
